Potential new treatment for advanced HER2-positive gastric cancer

University of the Sunshine Coast Clinical Trials is investigating a potential new treatment, for individuals with advanced gastric cancer. This trial investigates the use of a new anti-HER2 monoclonal antibody, in combination with trastuzumab and chemotherapy, for HER2-positive advanced gastric cancer. The study treatment targets the same domain of the HER2 protein as trastuzumab but binds to a different epitope, allowing both treatments to bind simultaneously, which may enhance their anti-cancer effects.

We are seeking applicants aged 18 years or older with advanced or metastatic gastric or gastroesophageal junction cancer that has not received any other anti-tumour treatments to participate in the study.

The trial will be overseen by our Principal Investigator at Sunshine Coast Haematology and Oncology Clinic (SCHOC) in Buderim on the Sunshine Coast and supported by our experienced clinical trials staff.

We are seeking applications from people who:

• are 18 years or older
• have a confirmed diagnosis of HER2-positive advanced or metastatic gastric or gastroesophageal junction cancer
• have not received any anti-tumour treatment for this advanced or metastatic cancer; however, radical surgery for earlier stages of the disease is permitted
• can commit to regular visits at our Buderim clinic on the Sunshine Coast

If you have patients who fit the criteria and who would be suitable for the trial, we would appreciate your consideration of their participation.

Participation will be free of charge and private health insurance is not required.

Please do not hesitate to contact us on 07 5456 3797 for further information.

Full title: A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer

HREC approval: St Vincent’s Hospital Human Research Ethics Committee